Sees 2025 total operating costs and expenses, excluding cost of goods sold, $116M-$121M. Sees 2025 total annual cash investment $25M-$30M and cash and cash equivalents to be sufficient to fund operations as currently planned into 2027.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs announces publication of Phase 2 interim results on naxitamab
- YMAB Earnings this Week: How Will it Perform?
- Y-mAbs Therapeutics presents translational pharmacokinetics data of GD2-SADA
- Y-mAbs Therapeutics Updates on Business and Clinical Trials
- Y-mAbs Therapeutics Announces Strategic Business Realignment